article thumbnail

In vitro 3D-engineered heart tissue that monitors drug-induced cardiotoxicity

Medical Xpress

Recently, a joint team of researchers from POSTECH and Georgia Institute of Technology successfully created an engineered heart via 3D printing technology that allows for early monitoring of drug-induced cardiotoxicity. The left ventricle's contractile ability is impaired, potentially leading to heart failure, a severe clinical outcome.

article thumbnail

Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies

Pharmaceutical Technology

The company can use its mammalian cell engineering expertise and capabilities to screen CAR T-cells, to discover and optimise next-generation therapeutic candidates for its partners. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models.

In-Vivo 264
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HP&M Welcomes Senior FDA Official, Ana Loloei, to the Firm

FDA Law Blog

Loloei tackled legal matters related to various aspects of the regulation of medical devices, in vitro diagnostics, and combination products including regulatory and compliance issues, dispute resolutions between the FDA and sponsors, and FDA enforcement actions. While at FDA, Ms. During her FDA tenure, Ms. Gibbs , HP&M Director.

article thumbnail

TFF and NIEHS partner to develop powder formulations for respiratory diseases

Pharmaceutical Technology

TFF Pharmaceuticals and NIEHS will investigate the TFF-HMW-HA formulations’ therapeutic efficacy and pharmacokinetics using in vitro and in vivo models of respiratory diseases.

article thumbnail

NKarta Therapeutics’ NKT Cells Elicit Better Response than CAR-T Cells Alone

BioSpace

NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to James Trager, CSO, speaking Wednesday at the virtual CAR-TCR Summit – Europe.

In-Vivo 87
article thumbnail

Pneumagen raises £8 million for further study of intranasal antiviral

Pharmaceutical Technology

Neumifil consists of an engineered carbohydrate-binding module domain of a Streptococcus pneumoniae protein. In April 2020, Pneumagen announced positive anti-viral activity results from three in vitro studies into preventing coronavirus infections, but the program has not yet been studied in humans. million ($4.75

In-Vitro 130
article thumbnail

6th Annual 3D Cell Culture Conference

pharmaphorum

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.